SG10201608307WA - Cd3 binding polypeptides - Google Patents

Cd3 binding polypeptides

Info

Publication number
SG10201608307WA
SG10201608307WA SG10201608307WA SG10201608307WA SG10201608307WA SG 10201608307W A SG10201608307W A SG 10201608307WA SG 10201608307W A SG10201608307W A SG 10201608307WA SG 10201608307W A SG10201608307W A SG 10201608307WA SG 10201608307W A SG10201608307W A SG 10201608307WA
Authority
SG
Singapore
Prior art keywords
binding polypeptides
polypeptides
binding
Prior art date
Application number
SG10201608307WA
Other languages
English (en)
Inventor
Philip Huat Tan
Sateesh Kumar Natarajan
Catherine J Mcmahan
Original Assignee
Emergent Product Dev Seattle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Product Dev Seattle filed Critical Emergent Product Dev Seattle
Publication of SG10201608307WA publication Critical patent/SG10201608307WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201608307WA 2012-04-20 2013-04-18 Cd3 binding polypeptides SG10201608307WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636557P 2012-04-20 2012-04-20
US201261718635P 2012-10-25 2012-10-25
US201361799849P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
SG10201608307WA true SG10201608307WA (en) 2016-11-29

Family

ID=49384230

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201406346SA SG11201406346SA (en) 2012-04-20 2013-04-18 Cd3 binding polypeptides
SG10201608307WA SG10201608307WA (en) 2012-04-20 2013-04-18 Cd3 binding polypeptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201406346SA SG11201406346SA (en) 2012-04-20 2013-04-18 Cd3 binding polypeptides

Country Status (16)

Country Link
US (1) US10202452B2 (pt)
EP (1) EP2839019A4 (pt)
JP (2) JP6509724B2 (pt)
KR (1) KR20150004856A (pt)
CN (1) CN104487587A (pt)
AU (2) AU2013249267A1 (pt)
BR (1) BR112014025830A8 (pt)
CA (1) CA2870545A1 (pt)
HK (2) HK1207398A1 (pt)
IL (1) IL235093B (pt)
IN (1) IN2014MN02293A (pt)
MX (1) MX366813B (pt)
RU (1) RU2673153C2 (pt)
SG (2) SG11201406346SA (pt)
UA (1) UA119227C2 (pt)
WO (1) WO2013158856A2 (pt)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
EP4342995A3 (en) 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
TWI807362B (zh) 2010-11-30 2023-07-01 日商中外製藥股份有限公司 細胞傷害誘導治療劑
WO2012145714A2 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
BR112014025830A8 (pt) 2012-04-20 2017-10-10 Emergent Product Dev Seattle Polipeptídeos de ligação ao cd3
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
RU2016134256A (ru) 2014-01-24 2018-03-05 Дзе Генри М. Джексон Фаундейшн Фор Дзе Эдвансмент Оф Милитари Медсин, Инк. Антитела против f гликопротеина вирусов хендра и нипах
WO2016001810A1 (en) 2014-07-01 2016-01-07 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
AU2015292406B2 (en) 2014-07-25 2021-03-11 Cytomx Therapeutics, Inc Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
BR112017014805A2 (pt) 2015-01-23 2018-01-09 Sanofi anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam especificamente a cd3 e/ou cd123
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
KR102405104B1 (ko) 2015-04-13 2022-06-07 화이자 인코포레이티드 치료 항체 및 그의 용도
MX2017013298A (es) 2015-04-13 2018-06-19 Pfizer Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b.
WO2016178996A1 (en) * 2015-05-01 2016-11-10 The Regents Of The University Of California Glycan-dependent immunotherapeutic molecules
AU2016263808B2 (en) 2015-05-21 2019-01-03 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
CN104892765B (zh) * 2015-06-29 2018-04-10 深圳市国创纳米抗体技术有限公司 一种抗CD3抗原和Her‑2抗原的双特异性抗体
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
CN108367004B (zh) * 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
US20170096485A1 (en) * 2015-10-02 2017-04-06 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
CA2997406A1 (en) 2015-12-09 2017-06-15 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release
SG10202007025PA (en) 2016-03-14 2020-08-28 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
CN107365387B (zh) * 2016-05-12 2022-03-15 阿思科力(苏州)生物科技有限公司 一种双特异性抗原结合构建体及其制备方法和应用
US11339225B2 (en) * 2016-05-12 2022-05-24 Asclepius (Suzhou) Technology Company Group, Co., Ltd. Bispecific antigen-binding construct and preparation method and use thereof
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CA3024683A1 (en) * 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single chain variable fragment cd3 binding proteins
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CA3059010A1 (en) 2016-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN106117358A (zh) * 2016-06-16 2016-11-16 中山大学 抗cd3单域抗体
CN106117361A (zh) * 2016-06-17 2016-11-16 中山大学 抗cd3单域抗体
CN106117360A (zh) * 2016-06-17 2016-11-16 中山大学 抗cd3单域抗体
CN106084048A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
CN106146661A (zh) * 2016-06-17 2016-11-23 中山大学 抗cd3单域抗体
CN106117359A (zh) * 2016-06-17 2016-11-16 中山大学 抗cd3单域抗体
CN106084046A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
CN106084047A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
CN106084049A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
EP3471773A4 (en) 2016-06-21 2020-07-08 Teneobio, Inc. ANTIBODIES BINDING CD3
CN106146662A (zh) * 2016-07-18 2016-11-23 中山大学 抗cd3单域抗体
CR20190198A (es) * 2016-09-14 2019-10-11 Teneobio Inc Anticuerpos de unión a cd3
WO2018057802A1 (en) * 2016-09-21 2018-03-29 Aptevo Research And Development Llc Cd123 binding proteins and related compositions and methods
AU2017363302A1 (en) 2016-11-23 2019-06-27 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
KR20210087108A (ko) 2016-11-23 2021-07-09 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
IL268836B2 (en) 2017-02-24 2024-04-01 Macrogenics Inc Bispecific molecules that bind CD137 and cancer antigens and their uses
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
BR112019023856A2 (pt) 2017-05-12 2020-06-09 Harpoon Therapeutics Inc proteínas triespecíficas que visam msln e métodos de utilização
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELINE BINDING PROTEINS
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
US11427642B2 (en) 2017-06-20 2022-08-30 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
CA3068056A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecifc antibody and uses thereof in cancer therapy
WO2019045856A1 (en) * 2017-08-28 2019-03-07 Systimmune, Inc. ANTI-CD ANTIBODIES AND METHODS OF MAKING AND USING THEM
BR112020007249B1 (pt) 2017-10-13 2022-11-22 Harpoon Therapeutics, Inc Roteína de ligação a antígeno de maturação de célula b, proteína de ligação multiespecífica e uso das referidas proteínas
BR112020007196A2 (pt) 2017-10-13 2020-12-01 Harpoon Therapeutics, Inc. proteínas triespecíficas e métodos de uso
JP2021501570A (ja) 2017-10-18 2021-01-21 ノバルティス アーゲー 選択的タンパク質分解のための組成物及び方法
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
WO2019108900A1 (en) 2017-11-30 2019-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
KR20200104342A (ko) 2017-12-22 2020-09-03 테네오바이오, 인코포레이티드 Cd22에 결합하는 중쇄 항체
TW201930591A (zh) 2018-01-08 2019-08-01 瑞士商諾華公司 用於與嵌合抗原受體療法併用之免疫增強rna
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019160904A1 (en) 2018-02-15 2019-08-22 Macrogenics, Inc. Variant cd3-binding domains and their use in combination therapies for the treatment of disease
CN112533950B (zh) * 2018-06-29 2023-03-10 多玛医药科技(苏州)有限公司 抗CD3e抗体及其用途
EP3817770A2 (en) 2018-07-02 2021-05-12 Amgen Inc. Anti-steap1 antigen-binding protein
EP3844267A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
AU2019345052A1 (en) * 2018-09-19 2021-03-18 FUJIFILM Cellular Dynamics, Inc. Protein L for activation and expansion of chimeric antigen receptor-modified immune cells
AU2019346466A1 (en) 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
TWI821474B (zh) * 2018-12-07 2023-11-11 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｄ３抗體及其藥物用途
WO2020168555A1 (zh) * 2019-02-22 2020-08-27 武汉友芝友生物制药有限公司 Cd3抗原结合片段及其应用
AU2020229806A1 (en) 2019-02-25 2021-07-29 Novartis Ag Mesoporous silica particles compositions for viral delivery
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
PE20220575A1 (es) 2019-06-14 2022-04-20 Teneobio Inc Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3
JP2023503163A (ja) 2019-11-26 2023-01-26 ノバルティス アーゲー キメラ抗原受容体及びその使用
JP2023512454A (ja) 2020-01-13 2023-03-27 アプティーボ リサーチ アンド デベロップメント エルエルシー タンパク質治療のための製剤
CA3164420A1 (en) 2020-01-13 2021-07-22 Jonathan Clapper Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
WO2021173985A2 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CA3182697A1 (en) 2020-05-11 2021-11-18 Janssen Biotech, Inc. Methods for treating multiple myeloma
IL298473A (en) 2020-06-11 2023-01-01 Novartis Ag zbtb32 inhibitors and uses thereof
KR20230058427A (ko) 2020-08-21 2023-05-03 노파르티스 아게 Car 발현 세포의 생체내 생성을 위한 조성물 및 방법
KR20230104617A (ko) * 2020-10-07 2023-07-10 드렌 바이오, 인크. 항-덱틴-1 항체 및 이의 사용 방법
WO2022109611A1 (en) 2020-11-20 2022-05-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
EP4330381A1 (en) 2021-04-27 2024-03-06 Novartis AG Viral vector production system
EP4330277A1 (en) * 2021-04-28 2024-03-06 NGM Biopharmaceuticals, Inc. Multimerization of binding molecules having an antibody constant region variant
KR20240005722A (ko) 2021-04-30 2024-01-12 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체를 사용한 치료를 위한 투약
TW202243689A (zh) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及抗ｃｄ７８ｂ抗體藥物結合物的組合治療之給藥
WO2022240865A1 (en) * 2021-05-11 2022-11-17 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
EP4341291A1 (en) 2021-05-21 2024-03-27 Aptevo Research and Development LLC Dosing regimens for protein therapeutics
AR126838A1 (es) 2021-08-20 2023-11-22 Novartis Ag Métodos para preparar células que expresan receptores de antígeno quiméricos
WO2023180353A1 (en) 2022-03-23 2023-09-28 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
JP2024517042A (ja) 2022-04-13 2024-04-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の薬学的組成物及び使用方法
CN115029318B (zh) * 2022-05-12 2022-12-20 成都赋智健康科技有限公司 携带多特异性抗体基因的间充质干细胞及其制药用途
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US20030108548A1 (en) 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
ES2375561T3 (es) 1994-01-11 2012-03-02 Dyax Corporation Inhibidores de la plasmina humana derivados de dominios kunitz y �?cidos nucleicos que codifican los mismos.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
WO1998003670A1 (en) 1996-07-23 1998-01-29 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
AU2719099A (en) 1998-01-23 1999-08-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Multipurpose antibody derivatives
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
WO2002040545A2 (en) * 2000-11-17 2002-05-23 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
RU2179862C1 (ru) * 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP2706116A1 (en) 2001-01-17 2014-03-12 Emergent Product Development Seattle, LLC Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20040044182A1 (en) 2001-09-17 2004-03-04 Hunt Joan S Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
CN100509850C (zh) 2003-05-31 2009-07-08 麦克罗梅特股份公司 用于治疗b细胞相关疾病的包含双特异性抗cd3、抗cd19抗体构建体的药物组合物
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
CN1950399A (zh) 2004-02-16 2007-04-18 麦克罗梅特股份公司 免疫原性较弱的结合分子
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
EP3178850B1 (en) 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
EP4342995A3 (en) * 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
NZ573132A (en) 2006-06-06 2012-05-25 Glaxo Group Ltd Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
WO2008051448A2 (en) 2006-10-19 2008-05-02 Tolerx, Inc. Methods and compositions for efficient removal of protein a from binding molecule preparations
EP2094302A4 (en) 2006-12-21 2010-12-08 Macrogenics Inc METHODS FOR THE TREATMENT OF LADA-LIKE DIABETES AND OTHER AUTOIMMUNE DIABETES OF THE ADULT USING IMMUNOSUPPRESSANT MONOCLONAL ANTIBODIES HAVING REDUCED TOXICITY
US20090148447A1 (en) 2007-07-06 2009-06-11 Trubion Pharmaceuticals, Inc. Binding Peptides Having a C-terminally Disposed Specific Binding Domain
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20110177070A1 (en) 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
MX2011000071A (es) 2008-07-02 2011-05-03 Emergent Product Dev Seattle Inmunoterapeuticos de interleucina-6 (il6).
US20110152173A1 (en) 2008-07-02 2011-06-23 Emergent Product Development Seattle ,LLC TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS
EP2321345A1 (en) 2008-07-28 2011-05-18 Emergent Product Development Seattle, LLC Multi-specific binding proteins targeting b cell disorders
AU2009296297A1 (en) 2008-09-26 2010-04-01 Roche Glycart Ag Bispecific anti-EGFR/anti-IGF-1R antibodies
KR20170091801A (ko) 2008-10-02 2017-08-09 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｃｄ86 길항제 다중-표적 결합 단백질
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US20110217302A1 (en) 2008-10-10 2011-09-08 Emergent Product Development Seattle, Llc TCR Complex Immunotherapeutics
TW201100543A (en) 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
CN102958942A (zh) 2009-12-29 2013-03-06 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
WO2012145714A2 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
KR101308922B1 (ko) * 2012-02-15 2013-09-23 주식회사 경동나비엔 연소기기용 듀얼 벤츄리
BR112014025830A8 (pt) 2012-04-20 2017-10-10 Emergent Product Dev Seattle Polipeptídeos de ligação ao cd3

Also Published As

Publication number Publication date
JP2018138039A (ja) 2018-09-06
IL235093B (en) 2019-09-26
IL235093A0 (en) 2014-12-31
MX2014012578A (es) 2015-05-11
HK1208707A1 (en) 2016-03-11
EP2839019A4 (en) 2016-03-30
UA119227C2 (uk) 2019-05-27
AU2017228643B2 (en) 2019-12-05
HK1207398A1 (en) 2016-01-29
RU2673153C2 (ru) 2018-11-22
US20150232557A1 (en) 2015-08-20
KR20150004856A (ko) 2015-01-13
MX366813B (es) 2019-07-25
CA2870545A1 (en) 2013-10-24
SG11201406346SA (en) 2014-11-27
CN104487587A (zh) 2015-04-01
JP6509724B2 (ja) 2019-05-08
AU2013249267A1 (en) 2014-10-23
BR112014025830A8 (pt) 2017-10-10
IN2014MN02293A (pt) 2015-08-07
RU2014142166A (ru) 2016-06-10
WO2013158856A2 (en) 2013-10-24
JP2015521032A (ja) 2015-07-27
AU2017228643A1 (en) 2017-10-05
US10202452B2 (en) 2019-02-12
EP2839019A2 (en) 2015-02-25
BR112014025830A2 (pt) 2017-06-20

Similar Documents

Publication Publication Date Title
HK1208707A1 (en) Cd3 binding polypeptides cd3
IL291571A (en) cx3cr1 binding polypeptides
HK1210964A1 (en) Immunotherapy with binding agents
HK1212711A1 (zh) 抗原結合蛋白
HK1204571A1 (en) Protease-regulated antibodies
IL233793A0 (en) mica binders
AP2014008102A0 (en) Anti-FcRn antibodies
HK1207656A1 (en) Albumin binding polypeptide
AP2015008266A0 (en) 1L-18 binding molecules
EP2875051A4 (en) ANTIBODIES AGAINST SIGLEC-15
GB201220474D0 (en) Polypeptides
HK1210793A1 (en) Abd binding polypeptide
PL2928935T3 (pl) Środki wiążące
HK1210186A1 (en) Anti-h7cr antibodies h7cr
EP2868485A4 (en) BINDER
PL2928936T3 (pl) Spoiwo
HK1207657A1 (en) Her3 binding polypeptides her3
EP2793918A4 (en) HDC-SIGN LINK PEPTIDES
GB201418608D0 (en) Peridinin-chlorophyll binding proteins
GB201200563D0 (en) Binding molecule
GB201203944D0 (en) Binding polypeptides
GB201103961D0 (en) Binding polypeptides
GB201214293D0 (en) Binding surfaces
PL2641462T3 (pl) Urządzenie wiążące
GB201211503D0 (en) Heparin binding peptides